Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis
Efficacy of abrocitinib and dupilumab on chronic hand eczema in patients with moderate-to-severe atopic dermatitis: results from the phase 3 JADE DARE Study
book_2
Source:
EADV Congress 2022 - Oral session
calendar_today
Published on Medfyle:
September 2022
import_contacts
4
min
In this medfyle
These exploratory analyses from JADE DARE support the use of abrocitinib in patients with moderate-to-severe AD and CHE.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a highlights summary of an oral session given at the EADV 2022 - 31st Congress and presented by:
Dr. Robert Bissonnette
Innovaderm Research
Montréal, QC, Canada
The content is produced by Infomedica, the official reporting partner of EADV 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
